These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 11, 2017
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the...
-
Nov 22, 2017
TSX VENTURE LISTING EXPECTED TO IMPROVE OPERATING EFFICIENCY, LOWER COSTS AND PROVIDE ENHANCED FINANCING FLEXIBILITY COMPANY'S SHARES TO REMAIN LISTED ON NASDAQ CAPITAL MARKET VANCOUVER and...
-
Sep 11, 2017
Updated data from ongoing Phase 1 trial presented at ESMO Confirmed EPI-506 is well-tolerated with a favorable safety profile Long-term stable disease and PSA reductions at higher dose levels in...
-
Sep 7, 2017
ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate...
-
Sep 1, 2017
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced that...
-
Aug 14, 2017
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial...
-
Jul 24, 2017
/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ HOUSTON and VANCOUVER, July 24, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the...
-
Jul 21, 2017
ESSA Pharma Inc. (TSX:EPI; NASDAQ:EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate...
-
Jul 20, 2017
ESSA Pharma Inc. (TSX:EPI; NASDAQ:EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate...
-
Jul 18, 2017
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ HOUSTON and VANCOUVER, July 18, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the...
-
Jul 13, 2017
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ HOUSTON and VANCOUVER, July 13, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the...
-
Jul 12, 2017
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ HOUSTON and VANCOUVER, July 12, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the...
-
Jun 5, 2017
Well tolerated to date with an acceptable safety profile Signs of clinical activity at the higher dose range Enrollment continues in additional cohorts at higher dose levels HOUSTON and VANCOUVER,...
-
May 17, 2017
ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate...
-
May 15, 2017
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial...
-
Apr 12, 2017
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today...
-
Apr 5, 2017ESSA Pharma Receives US$1.2 Million Grant Payment from Cancer Prevention Research Institute of Texas
ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer,...
-
Apr 3, 2017
ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer,...
-
Mar 14, 2017
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced that...
-
Mar 8, 2017
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders...
-
Feb 13, 2017
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial...
-
Feb 10, 2017
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced that...
-
Jan 30, 2017
ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company") a pharmaceutical company, currently in the clinical development stage, focused on the development of small molecule drugs for...
Dec 21, 2016Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
- Dec 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
- Dec 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
Dec 14, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial...
-
Nov 21, 2016
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of small molecule drugs for the treatment of prostate cancer, announced...
-
Sep 12, 2016
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced David...
-
Aug 12, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the third quarter and three months ended June 30, 2016. Amounts, unless specified...
-
Aug 1, 2016
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce today the appointment of Peter Virsik as Executive Vice President & Chief Operating Officer. Mr. Virsik...
-
May 13, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the second quarter and three months ended March 31, 2016. Amounts, unless specified...
-
Mar 21, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) announced today that Eventide Funds purchased 370,566 Common Shares from each of Marianne Sadar and Raymond Andersen, both...
-
Mar 21, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 1,666,666 common shares...
-
Mar 10, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders...
-
Feb 12, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the three months ended December 31, 2015. Amounts, unless specified otherwise, are expressed in
-
Jan 14, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce that it has completed its previously announced private placement (the "Private Placement") of 4,545,452...
-
Jan 7, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that Dr. David Parkinson has been appointed as the company's President and Chief Executive Officer effective...
-
Jan 6, 2016
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) announced today its intention to complete a private placement (the "Private Placement") of 4,545,454 units of the Company (each,...
-
Dec 15, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in...
-
Dec 14, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the year ended September 30, 2015. Amounts, unless specified otherwise, are expressed in...
-
Nov 24, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that the first patient has been enrolled in ESSA's Phase 1/2 clinical study of EPI-506 as a treatment for...
-
Nov 5, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that the Health Protection Branch ("HPB") of Health Canada has issued a 'no objection letter' for the Clinical...
-
Sep 23, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that the U.S. Food and Drug Administration ("FDA") has approved its Investigational New Drug ("IND") application...
-
Aug 17, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the third quarter and three months ended June 30, 2015. Amounts, unless specified...
-
Jul 28, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) is pleased to announce that it has received final approval for its common shares to be listed and commence trading on the Toronto Stock...
-
Jul 2, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that its common shares have been approved for listing and trading on the NASDAQ Capital Market ("NASDAQ") under the symbol...
-
Jun 24, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that it has appointed Dr. David Parkinson to its board of directors. Dr. Parkinson's appointment as an independent director...
-
May 28, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) today reported financial results for the second quarter and three and six months ended March 31, 2015. Amounts, unless specified otherwise,...
-
May 4, 2015
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that it has received notification from the Food and Drug Administration ("FDA" or the "Agency") in the US that the Company's...
